ArticleAAPS PharmSciTech2025
Co-amorphous Approach for Enhancing Rilpivirine Oral Bioavailability using CYP3A4 Inhibitor as a Co-former.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rilpivirine, a BCS class II drug, has low water solubility (0.0166 mg/ml) and oral bioavailability of (32%), limiting its HIV treatment delivery. This research aimed to improve rilpivirine's solubility and bioavailability by developing a co-amorphous system (CAMS) using nicotinamide as co-former. Nicotinamide selection was based on knowledge-based methods such as Hansen solubility parameter, Flory-Huggins interaction parameter, and molecular modeling. CAMS was prepared using solvent evaporation and quench cooling at molar ratio of 1:1, 1:2, and 2:1. Phase solubility study showed 1:1 molar ratio was most suitable for complex formation. Fourier transform infrared spectroscopy, powder X-ray diffraction, differential scanning calorimetry, and field-emission scanning electron microscopy confirmed CAMS formation. Saturation solubility studies showed rilpivirine's solubility increased 38-fold in CAMS compared to pure drug. In vitro drug release and ex vivo permeation study demonstrated 2.86- and 2.87-fold enhancement in drug release and permeation. Pharmacokinetic study in Wistar rats showed 2.49-fold improvement in oral bioavailability, attributed to improved dissolution and CYP3A4 enzyme inhibition by nicotinamide. Stability studies confirmed CAMS maintained its amorphous state for over three months, as shown by DSC, PXRD, FE-SEM, solubility and dissolution studies. The CAMS of rilpivirine and nicotinamide, prepared through solvent evaporation at 1:1 molar ratio, enhanced rilpivirine's solubility, dissolution, permeation, and oral bioavailability, offering a promising antiretroviral drug delivery strategy.
Indexed as
Identifiers
41188591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.